Pfizer reports positive results from Toviaz trial

Pfizer has published clinical trial data which demonstrates the efficacy of Toviaz, its new treatment for overactive bladder syndrome.

The company trialled the daily antimuscarinic agent against its own extended release therapy Detrusitol ER in order to compare the effectiveness of the newer drug.

It was found that Toviaz demonstrated significantly better performance in terms of reducing urge urinary incontinence (UUI) episodes and increasing bladder capacity when compared to both Detrusitol ER and placebo.

Pfizer states that the results of this study are important due to the rising prevalence of the condition, with rates set to increase due to the ageing nature of the population.

Dr Sender Herschorn of the Sunnybrook Health Sciences Centre in Toronto, who led the study, said: “This new data provides important information to physicians making treatment decisions for patients with overactive bladders.”

Last week, it was announced that Pfizer is to ally with MicuRx Pharmaceuticals and Cumencor Pharmaceuticals on research into promising new tuberculosis treatments.